Stephen P. Creekmore

3.3k total citations
45 papers, 2.0k citations indexed

About

Stephen P. Creekmore is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Stephen P. Creekmore has authored 45 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Immunology, 15 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Stephen P. Creekmore's work include Immune Cell Function and Interaction (22 papers), Immunotherapy and Immune Responses (11 papers) and CAR-T cell therapy research (9 papers). Stephen P. Creekmore is often cited by papers focused on Immune Cell Function and Interaction (22 papers), Immunotherapy and Immune Responses (11 papers) and CAR-T cell therapy research (9 papers). Stephen P. Creekmore collaborates with scholars based in United States and India. Stephen P. Creekmore's co-authors include Dan L. Longo, Richard I. Fisher, Thomas A. Waldmann, Jason L. Yovandich, Barry L. Gause, Floyd A. Benko, Lars Sternås, Maurizio Bendandi, Larry W. Kwak and Elaine S. Jaffe and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Journal of Geophysical Research Atmospheres.

In The Last Decade

Stephen P. Creekmore

45 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stephen P. Creekmore United States	23	1.4k	901	386	225	196	45	2.0k
A. W. Harris Australia	15	753 0.5×	914 1.0×	1.5k 4.0×	186 0.8×	421 2.1×	23	2.7k
Sherri Mudri United States	10	1.3k 0.9×	185 0.2×	311 0.8×	369 1.6×	105 0.5×	17	1.8k
Frederick M. Dirbas United States	26	592 0.4×	1.2k 1.3×	1.7k 4.4×	277 1.2×	549 2.8×	66	3.7k
Victoria Carlton United States	22	577 0.4×	592 0.7×	743 1.9×	97 0.4×	536 2.7×	50	2.4k
H. E. Ramsey United States	17	1.2k 0.8×	376 0.4×	678 1.8×	22 0.1×	44 0.2×	32	2.2k
Chung‐Wu Lin Taiwan	33	655 0.5×	965 1.1×	1.3k 3.5×	65 0.3×	615 3.1×	110	3.2k
Michael J. Wilson United Kingdom	17	1.9k 1.3×	224 0.2×	217 0.6×	43 0.2×	27 0.1×	28	2.2k
Debbie A. Law United States	18	691 0.5×	159 0.2×	579 1.5×	451 2.0×	29 0.1×	29	1.9k
Robert E. Wittes United States	21	162 0.1×	922 1.0×	618 1.6×	148 0.7×	320 1.6×	42	2.0k
Ruth Esser United States	28	1.4k 1.0×	1.3k 1.4×	472 1.2×	34 0.2×	35 0.2×	76	2.9k

Countries citing papers authored by Stephen P. Creekmore

Since Specialization

Citations

This map shows the geographic impact of Stephen P. Creekmore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen P. Creekmore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen P. Creekmore more than expected).

Fields of papers citing papers by Stephen P. Creekmore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen P. Creekmore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen P. Creekmore. The network helps show where Stephen P. Creekmore may publish in the future.

Co-authorship network of co-authors of Stephen P. Creekmore

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen P. Creekmore. A scholar is included among the top collaborators of Stephen P. Creekmore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen P. Creekmore. Stephen P. Creekmore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Conlon, Kevin C., E. Lake Potter, Stefania Pittaluga, et al.. (2019). IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion. Clinical Cancer Research. 25(16). 4945–4954. 95 indexed citations

Morishima, Chihiro, Douglas G. McNeel, Manish R. Patel, et al.. (2015). CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhIL-15) is associated with expansion of peripheral blood CD56+ NK cells and CD8+ T cells. Journal for ImmunoTherapy of Cancer. 3(S2). 1 indexed citations

Jiang, Man‐Shiow, Xiaoyi Yang, Dominic Esposito, et al.. (2015). Mammalian cell transient expression, non-affinity purification, and characterization of human recombinant IGFBP7, an IGF-1 targeting therapeutic protein. International Immunopharmacology. 29(2). 476–487. 5 indexed citations

Morishima, Chihiro, Douglas G. McNeel, Manish R. Patel, et al.. (2014). CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhil-15) is associated with robust expansion of peripheral blood CD56+ NK cells. Journal for ImmunoTherapy of Cancer. 2(S3). 2 indexed citations

Jiang, Hua, Yueqing Xie, Andrew Burnette, et al.. (2012). Purification of clinical-grade disulfide stabilized antibody fragment variable—Pseudomonas exotoxin conjugate (dsFv-PE38) expressed in Escherichia coli. Applied Microbiology and Biotechnology. 97(2). 621–632. 13 indexed citations

Waldmann, Thomas A., Kevin C. Conlon, Donn M. Stewart, et al.. (2012). Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia. Blood. 121(3). 476–484. 56 indexed citations

Vyas, Vinay, Dominic Esposito, James L. Hartley, et al.. (2011). Clinical manufacturing of recombinant human interleukin 15. I. Production cell line development and protein expression in E. coli with stop codon optimization. Biotechnology Progress. 28(2). 497–507. 16 indexed citations

Soman, Gopalan, Xiaoyi Yang, S L Giardina, et al.. (2009). MTS dye based colorimetric CTLL-2 cell proliferation assay for product release and stability monitoring of Interleukin-15: Assay qualification, standardization and statistical analysis. Journal of Immunological Methods. 348(1-2). 83–94. 33 indexed citations

Bendandi, Maurizio, Christopher D. Gocke, Carol B. Kobrin, et al.. (1999). Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma. Nature Medicine. 5(10). 1171–1177. 458 indexed citations

10.

Janik, John E., L.L. Miller, Daniele Longo, et al.. (1996). Phase II Trial of Interleukin 1 and Indomethacin in Treatment of Metastatic Melanoma. JNCI Journal of the National Cancer Institute. 88(1). 44–49. 22 indexed citations

11.

Curti, Brendan D., Augusto C. Ochoa, Walter J. Urba, et al.. (1996). Influence of Interleukin-2 Regimens on Circulating Populations of Lymphocytes After Adoptive Transfer of Anti-CD3-Stimulated T Cells. Journal of Immunotherapy. 19(4). 296–308. 17 indexed citations

12.

Norihisa, Y, Daniel W. McVicar, Paulomi Ghosh, et al.. (1994). Increased proliferation, cytotoxicity, and gene expression after stimulation of human peripheral blood T lymphocytes through a surface ganglioside (GD3). The Journal of Immunology. 153(2). 910–910. 33 indexed citations

13.

Curti, Brendan D., Daniele Longo, Augusto C. Ochoa, et al.. (1993). Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2.. Journal of Clinical Oncology. 11(4). 652–660. 34 indexed citations

14.

Sznol, Mario, J. W. Clark, John W. Smith, et al.. (1992). Pilot Study of Interleukin-2 and Lymphokine-Activated Killer Cells Combined With Immunomodulatory Doses of Chemotherapy and Sequenced With Interferon Alfa-2a in Patients With Metastatic Melanoma and Renal Cell Carcinoma. JNCI Journal of the National Cancer Institute. 84(12). 929–937. 26 indexed citations

15.

Smith, John W., W J Urba, J. W. Clark, et al.. (1991). Phase I Evaluation of Recombinant Tumor Necrosis Factor Given in Combination With Recombinant Interferon-Gamma. Journal of Immunotherapy. 10(5). 355–362. 19 indexed citations

16.

Steis, Ronald G., DL Longo, Jeffrey W. Clark, et al.. (1990). Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Advanced Malignancy: A Phase Ib Trial. JNCI Journal of the National Cancer Institute. 82(8). 697–703. 34 indexed citations

17.

Creekmore, Stephen P., James Harris, Thomas M. Ellis, et al.. (1989). A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions.. Journal of Clinical Oncology. 7(2). 276–284. 42 indexed citations

18.

Ellis, Tom, et al.. (1988). Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2.. PubMed. 48(22). 6597–602. 43 indexed citations

19.

McIlroy, M. B., et al.. (1976). Simultaneous Pulmonary Arterial Blood Velocity Measurements by Doppler Method and Pulmonary Capillary flow by Body Plethysmography. Clinical Science. 51(3). 13P–13P. 1 indexed citations

20.

Creekmore, Stephen P.. (1971). Direct-Channel Reggeization of Strong-Interaction Scattering Amplitudes. II. Physical review. D. Particles, fields, gravitation, and cosmology/Physical review. D. Particles and fields. 3(6). 1407–1418. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact